Current Strategies in the Treatment of Hematological Malignancies - Module 3

PROGRAM DESCRIPTION This webcast is intended to improve care of patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines ...

PROGRAM DESCRIPTION
This webcast is intended to improve care of patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options. This is part 3 of a 3-part series.

EDUCATIONAL OBJECTIVES
As a result of participating in the activity, learners should be better able to: Identify response assessment and management of tyrosine kinase inhibitor resistance in the treatment of chronic myeloid leukemiaEvaluate how compound genotypes are related to novel therapeutic option based outcomes in patients with acute myeloid leukemiaEvaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia

---

Write the first review

Resource tags